New eye drops show promise for fast dry eye relief
NCT ID NCT06309953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested Miebo eye drops in 99 adults with dry eye disease. Participants used one drop in each eye four times daily for 14 days. The main goal was to see how much dry eye symptoms improved after one week, measured on a 0-to-100 scale. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Miebo (perfluorohexyloctane ophthalmic solution)
What this could lead to
If successful, this could confirm that Miebo quickly relieves dry eye symptoms within a week, offering a new option for people with dry eye disease.
What could go wrong
This is a small, completed Phase 4 trial with no control group, so results may not prove effectiveness compared to placebo or other treatments. Individual results may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 201
Brecksville, Ohio, 44141, United States
-
Site 202
Kansas City, Missouri, 64154, United States
-
Site 203
Pittsburg, Kansas, 66762, United States
-
Site 204
Stillwater, Minnesota, 55082, United States
-
Site 205
Petaluma, California, 94954, United States
-
Site 206
Westlake, Ohio, 44145, United States
-
Site 207
Birmingham, Alabama, 35233, United States